Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, characterized by the Philadelphia translocation t (9, 22) , which generates the Bcr-Abl fusion gene and oncoprotein, representing a constitutively activated tyrosine kinase. The selective tyrosine kinase inhibitor Imatinib (formerly STI571, Gleevec ® ) blocks kinase activity by occupying the ATP binding site of the Abl tyrosine kinases Bcr-Abl, c-Abl, v-Abl and Abl-related gene (ARG), in addition to platelet-derived growth factor receptors (PDGF) alpha and beta and the receptor for human stem cell factor (SCF), c-kit. 1 Based on numerous studies in CML, including patients in early chronic phase (CP), 2,3 accelerated phase (AP) 4 and myeloid blast crisis (BC), 5 Imatinib is considered the new gold standard for conventional treatment of CML.
Unfortunately, resistance to Imatinib occurs frequently in AP and BC resulting in remissions usually lasting only for 6-12 months. Apart from second generation Bcr-Abl inhibitors that have recently been described, 6 ,7 identification of novel direct or indirect down-stream targets of Bcr-Abl could contribute significantly to the development of new synergistic treatment strategies in CML. Bcr-Abl regulates diverse signaling pathways involving Ras, phosphatidylinositol 3-kinase (PI3-K), protein kinase C (PKC), Jak-STAT, and NF-B. 8 Whereas consequences of Bcr-Abl inhibition have mostly been investigated at the RNA level, [9] [10] [11] [12] little is known about changes in global protein expression. 13, 14 The introduction of standardized 2-dimensional gel electrophoresis (2-DE) methods using immobilized ampholyte pH gradients, combined with mass spectrometry and bioinformatics-based protein database searches, has permitted screening of tumor-related global protein changes on a genome-wide scale. [15] [16] [17] [18] In the present study, we investigated the effects of Imatinib on the protein expression profiles of Bcr-Abl positive cells. Among others, we found eIF-5A, a protein involved in proliferation control, to be down-regulated under Imatinib treatment. Interestingly, eIF-5A is subject to
post-translational modification (PTM) called hypusination, representing the transfer of an
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From amino-butyl residue to lysine. 19 Several pharmacological substances are able to inhibit hypusination, rendering eIF-5A a potentially promising target protein for single agent as well as for combined treatment strategies. 20, 21 Therefore, we characterized the interaction between Imatinib and hypusination inhibitors (HI) in leukemic cell lines and primary CD34 + cells from CML patients at diagnosis. These results might have implications for the design of novel synergistic therapeutic strategies for patients with Bcr-Abl-positive leukemias and other
Imatinib-responsive diseases.
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Materials and Methods

Reagents
Imatinib, was. Imatinib (kindly provided by E. Buchdunger (Novartis, Basel, Switzerland) stock solution (10mg/ml; in DMSO/H 2 O (1:1)) was stored at -20°C. Ciclopirox (CPX) and N 1 -guanyl-1,7-diaminoheptane (GC7) were obtained from Sigma (Steinheim, Germany) and from Biosearch Technology (Novato, USA), respectively.
Cell culture techniques
K562, HL-60, and BA/F3 cells were obtained from DSMZ (Bielefeld, Germany). BA/F3 p210, T315I, M351T and E255K cells were kindly provided by C.L. Sawyers (UCLA, USA).
All cell lines were cultured in RPMI 1640 medium (Gibco-BRL, Invitrogen, UK) containing 10% fetal calf serum (FCS) (Biochrom KG, Berlin, Germany) and 1ng/mL recombinant murine interleukin-3 (IL-3) as indicated. The cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 .
Purification of stem and progenitor cells
Fresh leukapheresis, peripheral blood or bone marrow samples from CML patients were collected with informed consent. The study was approved by the ethics review board of the medical faculty of the University of Tübingen, Germany. CD34 + cells were selected using a Midi-MACS CD34 Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously. 
2-D gel electrophoresis
Protein samples were isolated from 10 7 K562 cells, yielding approximately 1000µg of protein.
Cells were lysed in sample buffer (9M urea, 4% CHAPS, 0.5% m/w Resolyte, 10µg/ml The individual protein spot quantity was normalized based on total density in the gel image and expressed as ppm. Quantitative analysis was performed using the student`s t-test between gels of treated and untreated cells. The confidence level was 95%.
Mass spectrometry
Protein spots of interest were excised from the gel, washed with Millipore-purified water and with 50% acetonitrile/water. In-gel protein digestion was performed as previously described with minor modifications. 25 After drying of excised gel spots, trypsin (sequencing grade, Promega, Mannheim, Germany) was added to each sample. Tryptic protein fragments were extracted from the gel matrix with 5% formic acid and with 50% acetonitrile/5% formic acid.
The extracts were pooled and concentrated in a speed vac concentrator. After purification with ZipTips (C18-ZipTip, Millipore, Bedford, MA, USA), aliquots were deposited on a spot of alpha-cyano-4-hydroxycinnamic acid/nitrocellulose and analysed with a Reflex III MALDI-TOF mass spectrometer (Bruker Daltonic, Bremen, Germany), equipped with an N 2
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 337nm laser. All measurements were performed in the positive-ion reflection mode at an accelerating voltage of 23kV and delayed-pulsed ion extraction. Sequence verification of tryptic fragments was performed by nano-electrospray tandem mass spectrometry on a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer (QSTAR Pulsar i, Applied Biosystems/MDS Sciex, Foster City, CA, USA) equipped with a nanoflow electrospray ionization source. Purified aliquots were loaded in a nano-electrospray needle (BioMedical Instruments, Zoellnitz, Germany) and tandem mass spectra were obtained by collision-induced decay of selected precursor ions. The instrument was calibrated externally.
Database searches (NCBInr, non-redundant protein database) were performed using the MASCOT software from Matrix Science with carboxymethylation of cysteine and methionine oxidations as variable modifications (probability value p<0.05).
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Western blotting
For protein extraction, cultured cells were homogenized on ice in lysis buffer containing 50mM Tris-HCl, pH7.5, 150mM NaCl, 1% NP-40, 0.25% Na-desoxycholate, 5mM EDTA, 1mM NaF, 25mM Na 3 VO 4 and 0.1 mM PMSF. The lysates were left on ice for 10 mins and cellular debris was pelleted at 14000 rpm for 20 mins at 4°C. The supernatant was frozen at -80°C. The protein concentration of the lysate was determined with the BCA Protein Assay Kit (Pierce, Rockford, USA). Proteins (20µg) were separated by 12.5% or 15% SDS-PAGE and transferred onto nitrocellulose membranes using the Bio-Rad Transblot system. After blocking in PBS-Tween/5% w/v milk powder for 1hr, membranes were incubated in primary antibody diluted in PBS-Tween/5% w/v milk powder. The following primary antisera were used: anti-vinculin: (Upstate, Lake Placid, USA), anti-β-Tubulin Ab-1 and anti-α-tubulin Ab-1 (Oncogene, Boston, USA), anti-nucleophosmin (Zymed, San Francisco, USA), and antiRan-binding protein (Upstate, Lake Placid, USA), anti-Phospho-CrKL (Cell Signaling, Danvers, USA), anti-Phospho-STAT5 (Cell Signaling, Danvers, USA), anti-Phospho-Tyrosin For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
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2-D gel electrophoresis of extracts from untreated versus Imatinib treated K562 cells
In order to detect proteins differentially expressed as a function of Bcr-Abl activity, K562 cells were incubated in the presence or absence of the Bcr-Abl inhibitor Imatinib for 24 or 48hrs. Representative coomassie stained 2D-gels of K562 cell extracts are shown in Figure   1A . In three independent experiments, using image analysis of the 2-D gels, we found a total of 19 protein spots reproducibly displaying a significantly different density dependent on Imatinib treatment at both time intervals (student´s t-test, p <0.05). Twelve protein signals were found to be down-regulated (highlighted in Figure 1A , left) and seven up-regulated (highlighted in Figure 1A , right). The nineteen protein signals were investigated by peptide mass fingerprinting and/or peptide sequencing (Table 1) . Expression patterns of selected differentially regulated candidate proteins were confirmed by Western blot analysis ( Figure   1B ). The expression changes of α-vinculin and Ran-binding protein were consistent with the 2-D electrophoretic analysis. One protein, eukaryotic initiation factor 5A (eIF-5A) (spot # 6, Figure 1A and close-up of all three gels in Figure 1C Furthermore, we extended our analysis to RNAs extracted from healthy donor PBMCs and PBMCs from CML patients lacking cytogenetic response because they were either untreated or treated with Hydroxyurea at the time of analysis. Clearly, eIF-5A mRNA is expressed at elevated levels in PBMCs from CML patients when compared with PBMCs from healthy donors ( Figure 1E ).
HI induce anti-proliferative effects in human leukemic cells
The activation of eIF-5A is regulated by a 2-step post-translational modification called hypusination. We therefore investigated the in vitro effects of two HI, CPX and GC7, which inhibit the first and second step of this process, on cellular viability and proliferation of K562 and HL-60 cells, using trypan blue exclusion. Treatment with increasing doses of CPX or GC7, respectively produced a dose-dependent reduction of cell growth after 24, 48 and 72hrs 
Co-treatment with Imatinib and HI synergised to induce cytotoxicity and apoptosis in K562 cells
In order to test pharmacological synergism of HI plus Imatinib by MTT assay, equitoxic ratios for testing the combination of Imatinib plus CPX or GC7, respectively, were chosen on the basis of the single drug concentration that led to a 50% growth inhibition in the target cell line. The results for both combinations are shown in isobologram plots ( Figures 3A,B) . For 50% inhibition (ED50), 75% inhibition (ED75) and 90% inhibition (ED90), points that fall to the left of the predicted line of additive effect, suggest a synergistic interaction of Imatinib and CPX ( Figure 3A ) and of Imatinib and GC7 ( Figure 3B ). When Imatinib was combined with CPX, a significant (P <0.05) synergistic effect became apparent at therapeutically relevant dose levels (P <0.05 at IC 50 ; IC 75 and IC 90 Table 3 ; CI values <1). Similar results were obtained when Imatinib was combined with GC7 (Table 3) .
We next asked whether Imatinib could sensitise Bcr-Abl-dependent cells to HI-induced apoptosis. For this purpose K562 cells were exposed for 24 hrs to increasing concentrations of CPX or GC7, in the presence or absence of sub-apoptotic concentrations of Imatinib (0.15µM). CPX and GC7 by themselves induced apoptosis in a dose dependent manner (black bars in Figures 3C and 3D, respectively) . However, when either CPX (grey bars, Figure 3C) or GC7 (grey bars, Figure 3D ) were combined with Imatinib, remarkable increases in the proportion of apoptotic cells were observed. Thus, sub-apoptotic concentrations of Imatinib dramatically increased HI-induced apoptosis in Bcr-Abl-positive K562 cells.
Treatment with HI does not affect phosphorylation of Bcr-Abl downstream targets in K562 cells
In order to investigate potential effects of HI treatment on specific phosphorylation of BcrAbl downstream targets, we studied both global tyrosine phosphorylation as well as phosphorylation of CRKL and STAT5 specifically under treatment with both CPX and GC7, respectively. As expected, treatment of K562 cells with Imatinib lead to both inhibition of global tyrosine phosphorylation and reduced levels of phosphorylated CRKL and STAT. In comparison, neither treatment with CPX nor with GC7 significantly affected the phosphorylation of tyrosine residues in general, nor of CRKL or STAT5 specifically. These findings argue against a direct effect of HI on the kinase activity of Bcr-Abl.
Stable lentiviral expression of siRNA directed against eIF-5A sensitises K562 cells to Imatinib with respect to proliferation
In order to further investigate the specificity of the anti-proliferative effects of HI on Bcr-Abl positive cells, we aimed to knock down eIF-5A in K562 cells. For this purpose, we stably expressed siRNA against eIF-5A and luciferase (negative control) in K562 cells by lentiviral gene transfer. First, the effect of eIF-5A-siRNA on eIF-5A-expression in K562 cells was confirmed at the mRNA level by RT-PCR ( Figure 3F ). For comparison, no significant downregulation of eIF-5A mRNA expression was detected in the cells following lentiviral transduction of luciferase-siRNA. These results demonstrate that eIF-5A-derived siRNA is highly specific for suppression of the eIF-5A expression.
We then tested for synergism between eIF-5A-siRNA expression and Imatinib treatment in K562 cells. For this purpose, we compared the anti-proliferative effects of Imatinib in K562 cells stably expressing siRNA against eIF-5A or luciferase as a control. As shown in Figure   3G , treatment with 0.15µM Imatinib for 48hrs led to a significant decrease in proliferation of K562 cells expressing eIF-5A siRNA, as compared to luciferase-siRNA expressing control K562 cells. In comparison, a significant suppression of expansion of CD34 + cells was already observed at a dose level of 1.25µM when cells were derived from untreated patients with CML ( Figure   7B ). This suggests that dose ranges can be selected at which CPX acts synergistically with
Imatinib on Bcr-Abl-positive cells, while leaving normal cells largely unaffected.
Co-treatment of Imatinib and HI synergistically induces cytotoxicity in CD34 positive cells from CML patients at diagnosis
We next determined the synergistic anti-leukemic effects of Imatinib and CPX or GC7, respectively against primary CML cells isolated from patients at diagnosis. As shown in in which Bcr-Abl dependent alterations in the Rho pathway were described in a murine background 13 , we found reduced expression of Rho-GDI under Imatinib treatment.
Furthermore, we detected Imatinib-induced down-regulation of eIF-5A, a protein highly conserved from yeast to mammalian cells. 36,37 EIF-5A precursor is the only cellular protein known to contain a specific lysine residue (Lys50) which is converted into the unique amino acid hypusine, thereby enabling activation of eIF-5A. Hypusination is induced stepwise via two distinct mechanisms. In the first step, catalysed by the enzyme deoxyhypusine-synthase, deoxyhypusine intermediates are formed by the transfer of 4-aminobutyl to lysine residues of the eIF-5A precursor. The second step involves hydroxylation of the side chain of the deoxyhypusine intermediates by a second enzyme called deoxyhypusine hydroxylase.
Hypusination plays a key role in the regulation of eIF-5A function. EIF-5A precursors that do not contain hypusine are barely active. 19 ,38 A series of observations suggests that eIF-5A plays a key role in cell growth and differentiation. 39,40 EIF-5A has been proposed to be an essential regulator of the nuclear export of some specific mRNAs. 41, 42 In addition, a minor human isoform, eIF-5A2, has been suggested to be an oncogene. 43 Hypusinylated eIF-5A contributes to the life cycle of human immunodeficiency virus by interacting with the retroviral REV protein, thereby participating in the nuclear export of unspliced and incompletely-spliced viral mRNA. 44, 45 Recently, it has been shown that inhibition of hypusination suppressed the replication cycle of HIV-1. Accordingly, deoxyhypusine synthase could also be used as a novel drug target in HIV treatment. Recently, Li et al. described a p53-dependent, proapoptotic function of eIF-5A in nonleukemic cells. 47 However, considering that K562 cells are p53 deficient and bearing in mind that loss of p53 is a typical feature of disease progression of CML from CP to AP/BC, these results are not in conflict with our observations. Interestingly, inhibition of hypusination has also been shown to be induced by treatment with Interferon-alpha in non-leukemic cells. 48, 49 In addition, combination of cytarabine with HI leads to synergistic anti-proliferative effects in human cancer cells. 50 Since both drugs are typically used for the treatment of CML patients and considering that both drugs act synergistically with Imatinib on Bcr-Abl-positive leukemias, these findings might provide the molecular background for the effects seen both in vitro and in vivo. 
